Fundamental Study of Pen-type Syringe Needles NANOPASS<sup>®</sup> II 34G4mm and NANOPASS<sup>®</sup> Jr. 34G3mm

DOI Web Site
  • Asakura Toshinari
    Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences

Bibliographic Information

Other Title
  • ペン型注入器専用針ナノパス<sup>®</sup>II（34G4mm）とナノパス<sup>®</sup>Jr.（34G3mm）の基礎的検討
  • Fundamental Study of Pen-type Syringe Needles NANOPASS Ⅱ 34G4mm and NANOPASS Jr. 34G3mm : Comparisons of Structure Influencing Patient's Self-injection Therapy
  • —Comparisons of Structure Influencing Patient’s Self-injection Therapy—
  • 〜患者の自己注射療法施行時に影響する構造上の比較〜

Search this article

Description

<p>Dedicated needles for pen-shaped self-injectable syringes for insulin or GLP-1 receptor activation (hereinafter referred to as injection needles) have been developed with the aim to reduce pain during injections. According to a study based on patients’ clinical experiences, a tendency has been reported that “the thinner and shorter the needles, the less painful patients feel”. In recent years, NANOPASS® Jr. 34G3mm with the needle length of 3mm (Terumo: TN34GT-J3) was launched, which we put to a fundamental test against the old tapered needles of NANOPASS® II 34G4mm needle (Terumo: TN34GT4). As a result, it was found that, while the piercing resistance was similar, the injection and flow path resistances of TN34GT-J3 were less than those of TN34GT4, with the strength evaluated from the deflection width and the number of bending times until breaking point was greater for TN34GT-J3. From these results, we noted that TN34GT-J3 is no inferior to TN34GT4 in any structural measurements and usable fundamentally as well as TN34GT4. Furthermore, with its shorter needle length potentially reducing intramuscular injection risks, it is considered useful for such patients with less subcutaneous fat at injection sites as children and lean patients.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top